- Home
- CALC vs CELU Comparison
CALC vs CELU Comparison
Compare CALC & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- CELU
- Stock Information
- Founded
- CALC 2011
- CELU 2016
- Country
- CALC United States
- CELU United States
- Employees
- CALC N/A
- CELU N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- CELU Health Care
- Exchange
- CALC Nasdaq
- CELU Nasdaq
- Market Cap
- CALC 36.0M
- CELU 42.2M
- IPO Year
- CALC N/A
- CELU N/A
- Fundamental
- Price
- CALC $1.85
- CELU $1.63
- Analyst Decision
- CALC Strong Buy
- CELU
- Analyst Count
- CALC 3
- CELU 0
- Target Price
- CALC $16.33
- CELU N/A
- AVG Volume (30 Days)
- CALC 63.1K
- CELU 102.4K
- Earning Date
- CALC 05-12-2025
- CELU 12-06-2024
- Dividend Yield
- CALC N/A
- CELU N/A
- EPS Growth
- CALC N/A
- CELU N/A
- EPS
- CALC N/A
- CELU N/A
- Revenue
- CALC N/A
- CELU $48,200,000.00
- Revenue This Year
- CALC N/A
- CELU N/A
- Revenue Next Year
- CALC N/A
- CELU $233.89
- P/E Ratio
- CALC N/A
- CELU N/A
- Revenue Growth
- CALC N/A
- CELU 225.94
- 52 Week Low
- CALC $1.81
- CELU $1.00
- 52 Week High
- CALC $6.27
- CELU $5.69
- Technical
- Relative Strength Index (RSI)
- CALC 36.21
- CELU 46.69
- Support Level
- CALC $1.81
- CELU $1.64
- Resistance Level
- CALC $2.10
- CELU $2.40
- Average True Range (ATR)
- CALC 0.16
- CELU 0.20
- MACD
- CALC 0.00
- CELU 0.01
- Stochastic Oscillator
- CALC 10.00
- CELU 17.20
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.